
Please try another search
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer’s disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson’s disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Eugen Steiner | 69 | 2017 | Independent Chairman |
Kaj Blennow | - | - | Member of Scientific Advisory Board |
Charlotta Ljungqvist | 63 | 2021 | Independent Director |
Staffan Pauli | - | - | Member of Scientific Advisory Board |
Martin Ingelsson | - | - | Member of Scientific Board |
Hans Wigzell | 86 | - | Member of Scientific Advisory Board |
Ken Marek | - | - | Member of Scientific Advisory Board |
Marie Cecilia Edström | 58 | 2023 | Independent Director |
Anna-Lena Engwall | 53 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review